# Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial

> **NCT07719738** · PHASE2 · COMPLETED · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 32 (actual)

## Conditions studied

- Biliary Cancer Metastatic

## Interventions

- **DRUG:** Bevacizumab+nab-paclitaxel+tegafur gimeracil oteracil potassium capsule (S-1)

## Key facts

- **NCT ID:** NCT07719738
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-02-23
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-02-23
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719738, "Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07719738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*